| Rinvoq (upadacitinib) / AbbVie |
NCT01741493: A Study in Healthy Adults and Adult Subjects With Rheumatoid Arthritis to Evaluate the Safety, Tolerability and Pharmacokinetics After Multiple Doses of ABT-494 |
|
|
| Completed | 1 | 67 | US | ABT-494, Placebo, Tofacitinib | AbbVie (prior sponsor, Abbott) | Rheumatoid Arthritis | 12/13 | 12/13 | | |
NCT06902987: Efficacy and Safety of Upatinib in the Treatment of Active Anal Fistulas in Crohn's Disease |
|
|
| Recruiting | 1 | 27 | RoW | Upadacitinib | Sixth Affiliated Hospital, Sun Yat-sen University | Crohn's Diseases, Active Anal Fistula, Upadacitinib | 12/25 | 12/26 | | |
NCT06379958: Drug-Drug Interaction (DDI) Study of Leramistat in Healthy Adult Subjects |
|
|
| Recruiting | 1 | 48 | Europe | leramistat 40mg, Itraconazole 200 mg, Phenytoin 100 Mg Oral Capsule, Simvastatin 40mg, Upadacitinib 15 MG | Modern Biosciences Ltd | Pharmacokinetics | 09/24 | 09/24 | | |
NCT03646604 / 2018-004409-17: A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Upadacitinib in Pediatric Participants With Severe Atopic Dermatitis |
|
|
| Completed | 1 | 35 | Europe, US | Upadacitinib (ABT-494), ABT-494, RINVOQ | AbbVie | Atopic Dermatitis | 08/24 | 08/24 | | |
NCT06684522: Upadacitinib As a Novel Treatment for Refractory Eyelid Dermatitis |
|
|
| Not yet recruiting | 1 | 10 | US | Upadacitinib 15 MG, RINVOQ | Northwestern University | Eyelid Dermatitis | 03/26 | 03/26 | | |
ChiCTR2300078576: The Effectiveness and Safety of Early Intervention with Maintenance dosage of Upadacitinib in mild active Ulcerative Colitis |
|
|
| Not yet recruiting | 1 | 120 | | sufficient mesalazine (≥ 3 grams per day) plus upadacitinib 15mg qd; sufficient mesalazine (≥ 3 grams per day) / sufficient mesalazine (≥ 3 grams per day) plus local suppositories or enemas | Peking University First Hospital; Peking University First Hospital, Researcher's spontaneous study | ulcerative colitis | | | | |
NCT03725007 / 2018-000715-25: A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Upadacitinib in Pediatric Subjects With Polyarticular Course Juvenile Idiopathic Arthritis |
|
|
| Active, not recruiting | 1 | 124 | Europe, Canada, Japan, US, RoW | Upadacitinib, ABT-494 | AbbVie, AbbVie Inc. | Juvenile Idiopathic Arthritis (JIA) | 05/27 | 05/27 | | |
